AMENDED AND RESTATED LICENSE AGREEMENT BETWEEN NAVIDEA BIOPHARMACEUTICALS, INC. AND THE REGENTS OF THE UNIVERSITY OF CALIFORNIA FOR CASE NO. SD1998-088License Agreement • March 9th, 2017 • Navidea Biopharmaceuticals, Inc. • In vitro & in vivo diagnostic substances • California
All fees and royalty payments specified in Paragraphs 3.1(a) through 3.1(g) above shall be paid by LICENSEE pursuant to Paragraph 4.3 and shall be delivered by LICENSEE to UNIVERSITY as noted in Paragraph 10.1.
WARRANT TO PURCHASE SHARES OF COMMON STOCKNavidea Biopharmaceuticals, Inc. • March 9th, 2017 • In vitro & in vivo diagnostic substances • Delaware
THIS CERTIFIES THAT, for value received, The Regents of the University of California (“Holder”), is entitled to subscribe for and purchase ONE MILLION (1,000,000) shares of fully paid and nonassessable shares of Common Stock of NAVIDEA BIOPHARMACEUTICALS, INC., a Delaware corporation (“Company”), at the Warrant Price (as hereinafter defined), subject to the provisions and upon the terms and conditions hereinafter set forth. As used herein, the term “Common Stock” shall mean Company’s presently authorized common stock, $0.001 par value per share, and any stock into which such Common Stock may hereafter be converted or exchanged and the term “Warrant Shares” shall mean the shares of Common Stock which Holder may acquire pursuant to this Warrant and any other shares of stock into which such shares of Common Stock may hereafter be converted or exchanged. Capitalized terms not otherwise defined herein shall have the respective meanings ascribed to them in the Asset Purchase Agreement, dated
LICENSE-BACK AGREEMENTLicense-Back Agreement • March 9th, 2017 • Navidea Biopharmaceuticals, Inc. • In vitro & in vivo diagnostic substances
This License-Back Agreement and its Exhibits (this “Agreement”), is entered into on March 3, 2017 (the “Effective Date”) between Cardinal Health 414, LLC, a Delaware limited liability company (the “Buyer”), and Navidea Biopharmaceuticals, Inc., a Delaware corporation (the “Seller”). Buyer and Seller are each individually referred to herein as a “Party” and are collectively referred to herein as the “Parties”.
GLOBAL SETTLEMENT AGREEMENTGlobal Settlement Agreement • March 9th, 2017 • Navidea Biopharmaceuticals, Inc. • In vitro & in vivo diagnostic substances • Texas
THIS GLOBAL SETTLEMENT AGREEMENT (this “Agreement”), dated as of March 3, 2017, is by and among NAVIDEA BIOPHARMACEUTICALS, INC., a Delaware corporation (“Navidea”) and MACROPHAGE THERAPEUTICS, INC., a Delaware corporation (“Macrophage” and, together with Navidea, collectively the “Company”), CAPITAL ROYALTY PARTNERS II L.P., a Delaware limited partnership, CAPITAL ROYALTY PARTNERS II (CAYMAN), L.P., a Cayman Islands limited partnership, CAPITAL ROYALTY PARTNERS II – PARALLEL FUND “A” L.P., a Delaware limited partnership, PARALLEL INVESTMENT OPPORTUNITIES PARTNERS II L.P., a Delaware limited partnership and CAPITAL ROYALTY PARTNERS II – PARALLEL FUND “B” (CAYMAN) L.P., a Cayman Islands limited partnership (each a “Lender” and, collectively, the “Lenders”), CRG SERVICING LLC, a Delaware limited liability company, as successor administrative agent (the “Agent”) and CARDINAL HEALTH 414, LLC, a Delaware limited liability corporation (“Cardinal Health”). The Company, the Lenders, the Agent
